Charles River To Merge With Leading Chinese Drug CRO WuXi PharmaTech If $1.6 Billion Transaction Is Approved By Beijing's Antitrust Czars

BEIJING - With the globe's top pharmaceutical players outsourcing ever-expanding chunks of early-stage research to China, the Massachusetts-based Charles River Laboratories has launched a move to merge with China's leading contract research organization, WuXi PharmaTech, in a $1.6 billion transaction